Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized vs IV Amikacin for HAP/VAP in Surgical ICU
NCT02728518Completed
- Start
- Aug 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of amikacin in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Primary endpoint: Proportion of cured patients at 1 year. Started Aug 2014; status: completed.
02
Drugs
amikacin
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02728518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728518.